Recent works aiming at a broad biological characterization of metastatic Hormone Receptor-positive, Human Epidermal growth factor Receptor 2-negative breast cancer (HR+ HER2- BC) have revealed a complex and heterogeneous genomic landscape [1–4]. The gene discussed is ERBB2; the disease is breast cancer.